Shares of Dendreon (DNDN) soared almost 15% after news that co. won FDA approval to sell a vaccine to treat men with advanced prostate cancer. The Provenge vaccine is the first vaccine to treat any type of cancer. – Reuters
Dendreon intends to make PROVENGE available through approximately 50 centers, all of which were approved PROVENGE clinical trial sites, and expects to increase capacity over the next year. The increased capacity will be a result of the anticipated licensure of its expanded New Jersey, Atlanta, Georgia and Orange County, Calif. facilities in mid-2011. – PR
Company will host a conference call today at 2:30PM ET
DNDN 45.50 +5.88 (14.84%) … Stock is halted.
Update: DNDN to resume trading @ 3:30PM ET
Dendreon CEO Dr. Mitchell Gold on Prostate Cancer vaccine:
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!